KBS - Pharmaceutical Consultancy and Life Sciences - Market Insight

M&A ACTIVITY CONTINUES TO RISE WITHIN THE PHARMA CONSULTANCY INDUSTRY

The UK pharmaceutical consultancy and life sciences industry is experiencing remarkable growth, with mergers and acquisitions (M&A) activity on the rise. This encompasses specialist providers supporting pharmaceutical companies, medical device manufacturers, biotechnology firms and healthcare organisations. Our extensive experience in managing successful transactions, allied to our ongoing engagement within this dynamic market, has provided us with a unique perspective. We have conducted an in-depth analysis of the company sales landscape within this sector, offering valuable insights into the key trends shaping sales activity. This includes the strategic moves of leading acquirers and the vital role of private equity in driving industry consolidation. We present significant industry transactions, highlighting notable deals and market dynamics that are reshaping the competitive landscape, along with a detailed overview of completed transactions facilitated by KBS Corporate, offering a practical look into real-world M&A examples within the pharma consultancy space.

CURRENT ACQUISITION TRENDS

Acquirers are targeting companies in order to:

• Enhance their core responsibilities and increase regulatory knowledge • Achieve faster, more efficient entry to market for products

• Capitalise on the growth of personalised medicine • Benefit from the growth of pharma services companies • Achieve consolidation

The most recently available government data showed the biopharmaceutical service and

supply sector increased by 13% to £23.5billion per annum , whereas the core biopharmaceutical increased by only 7% on the previous year to £40.8billion.